Conquer Cancer, the ASCO Foundation shared a post on LinkedIn:
“How do you turn an ultra-rare genetic mutation into a treatable condition?
You invest early in brilliant, out-of-the-box thinkers like Dr. Alison Schram.
When Dr. Schram began her oncology fellowship, researchers were traditionally expected to narrow their focus to a specific organ. But she saw a different path forward: following the raw biology and focusing entirely on a tumor’s unique genetic blueprint.
Backed early by Conquer Cancer funding, Dr. Schram’s persistent focus on genetic drivers recently led to a ‘double win’ in oncology.
Her global clinical trial secured a groundbreaking expanded FDA approval for a targeted therapy (zenocutuzumab-zbco) to treat aggressive, rare cancers.
Read more about Dr. Schram’s work: How Dr. Alison Schram’s Genetic Approach Unlocked Historic FDA Approvals.”
Other articles about Conquer Cancer, the ASCO Foundation on OncoDaily.